FindTrial
Sign In

NT 201 Placebo

DRUG4 trials

Sponsors

Merz Pharmaceuticals GmbH, Merz Aesthetics GmbH, Merz North America, Inc.

Conditions

Acetylcholine Release InhibitorsBotulinum Toxins, Type ACerebral PalsyCholinergic AgentsChronic Troublesome SialorrheaIntellectual DisabilityMembrane Transport ModulatorsMolecular Mechanisms of Pharmacological Action

Phase 2

A Study of NT 201 Doses in the Treatment of Platysma Prominence
CompletedNCT05773053
Merz Aesthetics GmbHPlatysma Prominence
Start: 2023-03-22End: 2024-01-24Updated: 2024-10-21

Phase 3

Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
CompletedNCT02270736
Merz Pharmaceuticals GmbHCerebral Palsy, Chronic Troublesome Sialorrhea, Intellectual Disability +2
Start: 2015-02-09End: 2019-05-07Updated: 2021-08-10
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
Active, not recruitingNCT07122193
Merz North America, Inc.Acetylcholine Release Inhibitors, Botulinum Toxins, Type A, Cholinergic Agents +7
Start: 2025-08-27End: 2027-09-01Updated: 2026-09-10
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)
Active, not recruitingNCT07210463
Merz Aesthetics GmbHAcetylcholine Release Inhibitors, Botulinum Toxins, Type A, Cholinergic Agents +7
Start: 2025-10-01End: 2027-08-01Updated: 2026-09-10

Related Papers

Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI.
2021-10-0419 citations